Compare FNWB & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWB | MGNX |
|---|---|---|
| Founded | 1923 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.9M | 94.9M |
| IPO Year | 2015 | 2013 |
| Metric | FNWB | MGNX |
|---|---|---|
| Price | $9.96 | $1.40 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 5 |
| Target Price | ★ $13.50 | $3.20 |
| AVG Volume (30 Days) | 31.1K | ★ 1.4M |
| Earning Date | 01-28-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $54,052,000.00 | ★ $127,626,000.00 |
| Revenue This Year | $31.86 | N/A |
| Revenue Next Year | $10.64 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.47 | N/A |
| 52 Week Low | $6.05 | $0.99 |
| 52 Week High | $12.10 | $3.60 |
| Indicator | FNWB | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 64.85 | 44.77 |
| Support Level | $9.80 | $1.32 |
| Resistance Level | $10.14 | $1.47 |
| Average True Range (ATR) | 0.21 | 0.08 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 46.15 | 34.78 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.